Simvastatin Reduces Expression and Activity of Lipoprotein-Associated Phospholipase A2 in the Aorta of Hypercholesterolaemic Atherosclerotic Rabbits
Authors:
- 1 August 2009
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 37 (4) , 1029-1037
Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2) contributes to atherosclerotic plaque instability and subsequent sudden coronary death. Statins are associated with decreased stroke risk and may improve stability of atherosclerotic plaques. The present study investigated the effect of simvastatin on expression of Lp-PLA2 levels in atherosclerotic plaques and on Lp-PLA2 activity in atherosclerotic aortas. Rabbits were a fed chow (control group) or a high-cholesterol diet (atherosclerosis group) for 12 weeks. An additional group on the high-cholesterol diet received simvastatin (5 mg/kg per day) for the last 4 weeks (simvastatin group). Lp-PLA2 activity in plasma and atherosclerotic aortas was significantly higher in the atherosclerosis group than in the control group and, consistent with this, abundant Lp-PLA2 protein was detected in plaques in the atherosclerosis group. Simvastatin significantly reduced Lp-PLA2 activity in plasma and aorta tissue, and reduced Lp-PLA2 protein level in atherosclerotic plaques. Whereas there was no significant difference in total atherosclerotic lesion area between simvastatin and atherosclerosis groups, simvastatin significantly reduced macrophage content, lipid retention and the intima/media ratio but increased the content of smooth muscle cells in atherosclerotic lesions. Thus, statin treatment markedly reduced Lp-PLA2 in both plasma and atherosclerotic plaques. This was associated with attenuation of the local inflammatory response and improved plaque stability.Keywords
This publication has 20 references indexed in Scilit:
- Platelet-Activating Factor, PAF Acetylhydrolase, and AnaphylaxisNew England Journal of Medicine, 2008
- The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohortAtherosclerosis, 2007
- Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentrationAtherosclerosis, 2006
- Advanced Oxidation Protein Products Accelerate Atherosclerosis Through Promoting Oxidative Stress and InflammationArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) StudyCirculation, 2004
- Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- The evolving role of statins in the management of atherosclerosisJACC, 2000
- Antiatherothrombotic Properties of StatinsJAMA, 1998
- Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.Proceedings of the National Academy of Sciences, 1983